Figure 4.

Application of fBSLBs to study blocking efficacy of neutralizing antibodies in human blood serum samples. Scheme showing the processing of human serum samples to quantify amount of anti-Spike IgGs and their capacity to block the interaction between Sp⁺VLPs and ACE2-fBSLBs. (A) Plot illustrates the serum-I-normalized medians of three different biological replicates to quantify the amount of anti-Spike IgGs in three different serum samples at different dilutions. (B) Plot shows the positive-control-normalized medians of three different biological replicates to quantify the blocking efficiency between Sp⁺VLPs and ACE2-BSLBs for the three different serum samples in panel A. The amount of anti-Spike-IgGs in the serum samples correlates with blocking efficiency. Illustrations were created using Biorender.com and Inkscape.